In Vitro Antiviral Testing
A key step in drug discovery is screening to evaluate antiviral activity. After determining the appropriate compounds and mechanisms, the next step is to perform cytotoxicity analysis of the compounds to ensure your efficacy data are meaningful and within a reasonable therapeutic window. Here is a short list of antiviral assays.
Cytopathic effect (CPE) inhibition assay. CPE is morphological changes in cells caused by cytopathogenic virus infection. CPE assay is used to evaluate test articles’ ability to inhibit CPE. This is the most cost-effective and time-efficient assay we offer for high throughput screening of overall antiviral activity. For non-cytopathic viruses we offer cell-based enzyme-linked immunosorbent assay (ELISA) or quantitative real-time Polmerase Chain Reaction (PCR) assay.
Cell-based ELISA. Cell-based ELISA measures reduction of viral antigen in infected cells using anti-virus monoclonal antibody. The abundance of viral protein in infected cells treated with the test article compared to that of the untreated control is used as a measure of antiviral activity.
qPCR assay. qPCR assay uses oligonucleotide primers and a probe amplifying virus-specific target sequence to detect the presence of virus nucleic acids. Reduction of virus nucleic acid in infected cells is used an indicator of a test article’s antiviral efficacy.
Plaque reduction assay. Infectious virus particles multiply in cells and result in circular zones of infected regions, plaques. Plaque reduction assay measures the plaque forming efficiency of a virus in the presence of different concentrations of a test article. Plaque reduction neutralization test (PRNT), a variation of this assay, is considered the gold standard for detecting neutralizing antibodies to certain viruses (i.e., flavivirus).
Yield reduction assay. Yield reduction assay is a labor-intensive but powerful technique for evaluating a compound’s antiviral efficacy. The three-step assay involves: infecting cells in the presence of different concentrations of the test article; collecting the cells or cell culture supernatants after a cycle of virus replication; and determining virus titers by plaque assay, TCID50, or quantitative real-time PCR.
Antibody-dependent enhancement (ADE) assay. ADE occurs when non-neutralizing or sub-neutralizing antiviral proteins facilitate virus entry into host cells leading to enhanced infectivity. ADE, which has been observed in viruses such as Dengue and Influenza, poses a challenge in vaccine development. Using flow cytometry, plaque assay or qPCR, this assay evaluates the ADE effect of test articles on virus infection in Fc receptor bearing cells.
Hemagglutination-inhibition test (HAI). HAI assay tests the efficacy of influenza vaccine candidates in preventing virus-induced hemagglutination. We offer HAIs against H1, H7 and H10 subtypes of the Influenza virus.
Quantitative suspension/carrier test. This test is used to evaluate virucidal activity of chemical disinfectants within a given contact time in suspension or on a non-porous surface. Generally, a 4 log10 reduction in virus titer (99.9% inactivation) is an indicator of a disinfectant’s virucidal properties detected under the test conditions.
IBT Bioservices offers a set of assays in key virus families. We can help you select the appropriate assays for your specific compound and mechanism of action, as outlined in the table on the following page. If you don’t see your pathogen we can provide additional validations upon request. Just contact us for a consultation and a no obligation quote.